Payment overview · 2025
General Payments
$224.38
9 reported records · 7 companies
Healthcare provider profile · identity verified
Sherry J Castillo, MD
Allopathic & Osteopathic Physicians|Family Medicine · MEDFORD, OR · NPI 1689799405
Verified facts
What the public records show
CMS Open Payments records show Sherry J Castillo, MD received $224.38 in general payments during 2025 across 9 reported records.
Astellas Pharma US Inc accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.82 | 23.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.29 | 21.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.00 | 13.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $26.58 | 11.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.37 | 11.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.29 | 11.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.03 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.38 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.82 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 52 |
| Metformin Hcl Er | Metformin Hcl | 103 | 27 |
| Gabapentin | Gabapentin | 102 | 30 |
| Lisinopril | Lisinopril | 96 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 95 | 31 |
| Losartan Potassium | Losartan Potassium | 92 | 36 |
| Simvastatin | Simvastatin | 83 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 18 |
| Potassium Chloride | Potassium Chloride | 51 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 15 |
| Estradiol | Estradiol | 45 | 20 |
| Omeprazole | Omeprazole | 45 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | suppressed |
| Meloxicam | Meloxicam | 40 | 16 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Trazodone Hcl | Trazodone Hcl | 40 | 17 |
| Eliquis | Apixaban | 39 | 11 |
| Furosemide | Furosemide | 38 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 13 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 32 | 15 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 11 |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Progesterone | Progesterone, Micronized | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Metformin Hcl | Metformin Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.38 · 9 records | Astellas Pharma US Inc | CAPVAXIVE, FARXIGA, GARDASIL 9, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VAXNEUVANCE, Veozah, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error